CCCatarina Falcão de Campos

Catarina Falcão de Campos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catarina Falcão de Campos has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Isabel Conceição

    ULS Santa Maria, CAML, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

    6 shared publications
  • Mamede de Carvalho

    Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

    6 shared publications
  • Isabel Conceição

    Department of Neurology Hospital Santa Maria, ULS Santa Maria Lisbon Portugal

    4 shared publications
  • Mamede de Carvalho

    University of Lisbon

    4 shared publications
  • Miguel Oliveira Santos

    Department of Neurology Hospital Santa Maria, ULS Santa Maria Lisbon Portugal

    4 shared publications
  • Hilmi Uysal

    Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

    3 shared publications

Latest Publications

  • Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies

    by Catarina Falcão de Campos, Isabel de Castro, José Castro, Inês Losada Lopez, Juan Gonzalez Moreno, Isabel Conceição

    Introduction/Aims: Transthyretin ( TTR ) stabilizers and gene‐silencing therapies are approved for hereditary transthyretin‐mediated amyloidosis with polyneuropathy ( ATTRv ‐ PN ), but data from clinical practice in patients who transition between therapies due to disease progression remains limited. The primary aim of this study is to evaluate the effectiveness of patisiran in ATTRv ‐ PN patients who progressed despite prior treatment with tafamidis 20 mg. Methods: We conducted a retrospective multicenter observational study including patients with ATTRV30M (p.V50M) with polyneuropathy who were initially treated with tafamidis 20 mg and subsequently switched to patisiran due to documented neuropathy progression. Patients had at least 12 months of follow‐up under each treatment. Neuropathy progression was assessed using the Neuropathy Impairment Score (NIS), neurophysiological composite scores, nutritional status, serum biomarkers, and patient‐reported outcomes. Results: Thirty‐two patients (mean age 52 ± 14 years; mean disease onset 43 ± 23.5 years) were included. Median disease duration before treatment initiation was 1.8 ± 1.9 years. The mean duration of tafamidis and patisiran treatment was 4.5 ± 2.8 and 2.5 ± 2.3 years, respectively. The annual increase in NIS was significantly lower during patisiran treatment than during tafamidis (0.7 ± 3.9 vs. 3.9 ± 4.7; p = 0.004). Decline in neurophysiological parameters slowed after switching. Discussion: In this cohort, patisiran attenuated neuropathy progression in patients who had deteriorated despite tafamidis. These findings highlight the importance of ongoing clinical monitoring to guide timely treatment optimization.

  • Open Access

    Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis

    by Simão Cruz, Anabela Matos, Luís Braz, Catarina Falcão Campos, João Cerqueira, Luísa Medeiros, Ernestina Santos, Luís Santos, Andreia Veiga

    Myasthenia gravis is an autoimmune disease that affects the neuromuscular junction, mainly through the action of pathogenic antibodies such as those directed against the nicotinic acetylcholine receptor or, more infrequently, against the muscle specific kinase. Other important components of the autoimmune process include the complement pathway and B and T cell populations. Diagnosis is based on the finding of fatigable muscle weakness, which can affect several muscle groups, either in isolation or in variable combinations. Neurophysiological techniques and/or the detection of pathogenic antibodies in serum are also essential for the diagnosis of myasthenia gravis. Maintenance treatment was traditionally based on corticosteroids and non-steroidal immunosuppressants. Recently approved drugs, such as the terminal complement pathway inhibitors and the neonatal Fc receptor antagonists, are reshaping the treatment landscape, supported by robust evidence of an excellent combination of efficacy and safety. Although several international guidelines have been published in the last decade, some key questions remain without precise guidance. Hence, a group of nine experts from the Portuguese Neuromuscular Society has elaborated consensus guidelines that aim to provide detailed guidance on diagnostic workup and treatment, grounded both in published evidence and in clinical experience. Key novel aspects include step-by-step instructions for diagnostic workup, a set of diagnostic criteria, guidance on the use of complement inhibitors and neonatal Fc receptor antagonists, and tailored treatment algorithms according to antibody subgroup and clinical severity.

  • Neuropathy Progression in Acquired Amyloidosis After Domino Liver Transplantation

    by Catarina Falcão de Campos, Miguel Miranda, Isabel Castro, José Castro, Miguel Oliveira Santos, Isabel Conceição

    Background and Aims: Domino liver transplantation (DLT) has been used to address the shortage of donor organs. However, recipients of liver grafts from patients with hereditary transthyretin amyloidosis (ATTRv) develop de novo transthyretin (TTR) amyloidosis. Our aim is to describe the clinical presentation of patients with acquired TTR amyloidosis and compare the rate of neuropathy progression (NP) with untreated ATTRv amyloidosis with neuropathy (ATTRv‐NP) patients.Methods: Patients with acquired TTR amyloidosis after DLT followed at a reference centre were evaluated. Medical records were reviewed for clinical characterization and systematic assessment of neuropathy. NP was defined as an increase in neuropathy impairment score of the lower limbs (NIS‐LL) at 12 months and compared to a historical control group of untreated ATTRv amyloidosis patients.Results: Twenty‐four patients with acquired ATTR amyloidosis were included. Time from DLT to neuropathy onset was 9 2.0 years and the majority of patients reported feet sensory changes as first symptom. Thirteen patients with ≥ 2 evaluations with 12‐months interval were analysed. Almost all patients developed a neuropathic phenotype with small nerve fibre involvement. Neuropathy progression was similar to untreated ATTRv‐NP patients.Interpretation: Recipients from liver grafts of ATTRv patients develop de novo amyloidosis with clinical presentation and NP similar to untreated ATTRv amyloidosis patients. Study of these patients might help elucidate the pathways for ATTR fibril formation.


  • Open Access

    Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis

    by Bernardo Antunes, Isabel Conceição, Catarina Falcão de Campos, Mamede de Carvalho

    Background: Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) is a rare progressively incapacitating condition with a wide range of genotype/phenotype presentations. It is frequently diagnosed late in its course, particularly in sporadic cases. Objectives: Analysing predictors of diagnostic delay in this subpopulation should be, therefore, a priority. Methods: 109 apparently sporadic ATTRv amyloidosis patients followed in a reference centre in Hospital de Santa Maria (ULS Santa Maria-CAML), in Lisbon, were studied. Time from symptom onset to diagnosis, age, sex, municipality of origin and initial symptoms were obtained. Diagnostic delay was compared between different decades with a Kruskal–Wallis test, and its predictors were evaluated in a univariate model followed by a binary logistic regression analysis to calculate the adjusted odds ratio. Results: The median diagnostic delay was 1262 days. There was a non-significant difference in diagnostic delay between the 80 s, 90 s, 2000s and 2010s decades. There was a non-significant trend for a longer diagnostic delay in woman and in patients having no neurologic symptoms at onset. Conclusion: There is an important diagnostic delay in sporadic cases of ATTRv amyloidosis. Awareness should be spread among clinicians regarding the various manifestations of this disease, stressing the importance of family history and epidemiological data.


  • Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function

    by Catarina Serrão, Sara Domingues, Catarina Falcão de Campos, Susana Moreira, Isabel Conceição, Mamede de Carvalho, Miguel Oliveira Santos

    Introduction Nusinersen was approved for 5q spinal muscular atrophy (SMA), irrespective of age, SMA type or functional status. Nonetheless, long-term data on adults with milder phenotypes are scarce. We aimed to characterize evolution on motor and respiratory function in our cohort of adults with type 3 SMA. Methods We conducted a longitudinal retrospective single-center study, including adults (≥18 years) with type 3 SMA under nusinersen for > 22 months. We reported on motor scores and spirometry parameters. Results Ten patients were included, with a median follow-up of 34 months (range = 22–46). Four patients (40%) were walkers. None used non-invasive ventilation. In Revised Upper Limb Module (RULM) and Expanded Hammersmith Functional Motor Scale (HFMSE), difference of medians increased at 6, 22 and 46 months comparing to baseline (−0.5 vs. + 1.5 vs. + 2.5 in RULM; + 4.0 vs. + 7.5 vs. + 6.0 in HFMSE). Two (50%) walkers presented a clinically meaningful improvement in 6-min walk distance. We did not report any clinically meaningful decrement in motor scores. Spirometry parameters showed an increasing difference of medians in maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) (−3 vs. + 13.4 vs. + 28.7 percentage points of predicted value for MIP; + 11.8 vs. + 13.1 vs. 13.3 percentage points of predicted value for MEP). Discussion Our cohort supports a sustained benefit of nusinersen in adults with type 3 SMA, in motor and respiratory function. Multicentric studies are still warranted.


  • Multisystemic RFC1 -Related Disorder

    by Maria João Malaquias, Luis Braz, Cláudia Santos Silva, Joana Damásio, André Jorge, João M. Lemos, Catarina F. Campos, Daniela Garcez, Miguel Oliveira Santos, Ana G. Velon, et al.

    Background and Objectives The RFC1 spectrum has become considerably expanded as multisystemic features beyond the triad of cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) have started to be unveiled, although many still require clinical replication. Here, we aimed to clinically characterize a cohort of RFC1-positive patients by addressing both classic and multisystemic features. In a second part of this study, we prospectively assessed small nerve fibers (SNF) and autonomic function in a subset of these RFC1-related patients. Methods We retrospectively enrolled 67 RFC1-positive patients from multiple neurologic centers in Portugal. All patients underwent full neurologic and vestibular evaluation, as well as neuroimaging and neurophysiologic studies. For SNF and autonomic testing (n = 15), we performed skin biopsies, quantitative sensory testing, sudoscan, sympathetic skin response, heart rate deep breathing, and tilt test. Results Multisystemic features beyond CANVAS were present in 82% of the patients, mainly chronic cough (66%) and dysautonomia (43%). Other features included motor neuron (MN) affection and motor neuropathy (18%), hyperkinetic movement disorders (16%), sleep apnea (6%), REM and non-REM sleep disorders (5%), and cranial neuropathy (5%). Ten patients reported an inverse association between cough and ataxia severity. A very severe epidermal denervation was found in skin biopsies of all patients. Autonomic dysfunction comprised cardiovascular (67%), cardiovagal (54%), and/or sudomotor (50%) systems. Discussion The presence of MN involvement, motor neuropathy, small fiber neuropathy, or extrapyramidal signs should not preclude RFC1 testing in cases of sensory neuronopathy. Indeed, the RFC1 spectrum can overlap not only with multiple system atrophy but also with hereditary motor and sensory neuropathy, hereditary sensory and autonomic neuropathy, and feeding dystonia phenotypes. Some clinical-paraclinical dissociations can pose diagnostic challenges, namely large and small fiber neuropathy and sudomotor dysfunction which are usually subclinical.


  • Open Access

    Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy

    by Catarina Falcão de Campos, Isabel Conceição

    Hereditary amyloid transthyretin (ATTRv) amyloidosis is a devastating hereditary multisystemic disease affecting predominantly the peripheral and autonomic nervous systems and the heart. ATTRv is caused by mutations in the transthyretin (TTR) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. If untreated, it is associated with a fatal outcome 10– 12 years after disease onset. Different treatments are available for patients with ATTRv polyneuropathy. Tafamidis 20 mg is approved in Europe since 2011 for early stages of ATTRv polyneuropathy (stage I – able to walk without support) and it is recommended as first-line therapy in these patients. Tafamidis is a TTR stabilizer that selectively binds to TTR and kinetically stabilizes both wild-type native TTR and mutant TTR. Consequently, it has the potential to prevent the amyloidogenic cascade initiated by TTR tetramer dissociation into its monomers and subsequent misfolding and aggregation. Tafamidis is an oral drug, taken once per day, with proved efficacy, safety and tolerability in ATTRv-PN patients as demonstrated in different clinical trials and open-label extension studies as well in clinical practice setting with around 10 years of experience. Tafamidis treatment started in the earliest stages of the disease is associated with better neurological outcomes. A multidisciplinary approach in referral centres is also fundamental for monitoring patients to assess individual response to treatment.


  • Open Access

    Trends in the diagnostic delay and pathway for amyotrophic lateral sclerosis patients across different countries

    by Catarina Falcão de Campos, Marta Gromicho, Hilmi Uysal, Julian Grosskreutz, Magdalena Kuzma-Kozakiewicz, Miguel Oliveira Santos, Susana Pinto, Susanne Petri, Michael Swash, Mamede de Carvalho

    Background: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with a median survival of 2–5 years. An early diagnosis is essential for providing ALS patients the finest management possible. Studies from different countries report a similar median diagnostic delay of around 12 months, which is still far from desirable. We analyzed the diagnostic pathway in different countries in order to identify the major challenges.Methods: We studied a cohort of 1,405 ALS patients from five different centers, in four different countries (Turkey, Germany, Poland, and Portugal), which collaborated in a common database. Demographic, disease and sociocultural factors were collected. Time from first symptom onset to first medical evaluation and to diagnosis, the specialist assessment and investigations requested were analyzed. Factors contributing to diagnostic delay were evaluated by multivariate linear regression.Results: The median diagnostic delay from first symptom onset was 11 months and was similar between centers. Major differences were seen in the time from symptom onset to first medical evaluation. An earlier first medical evaluation was associated with a longer time to diagnosis, highlighting that ALS diagnosis is not straightforward in the early stages of the disease. The odds for ALS diagnosis were superior when evaluated by a neurologist and increased over time. Electromyography was decisive in establishing the diagnosis.Conclusions: We suggest that a specific diagnostic test for ALS—a specific biomarker—will be needed to achieve early diagnosis. Early referral to a neurologist and to electromyography is important for early ALS diagnosis.


  • Open Access

    Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?

    by Catarina Falcão de Campos, Marta Gromicho, Hilmi Uysal, Julian Grosskreutz, Magdalena Kuzma-Kozakiewicz, Miguel Oliveira Santos, Susana Pinto, Susanne Petri, Michael Swash, Mamede de Carvalho

    Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with unsatisfactory treatment options. Best management and recruitment into clinical trials requires early diagnosis. However, diagnosis is often delayed. Analysis of the diagnostic pathway and identification of the causes of diagnostic delay are imperative.Methods: We studied a cohort of 580 ALS patients followed up in our ALS clinic in Lisbon. Demographic, disease, and sociocultural factors were collected. Time from first symptom onset to diagnosis, the specialist's assessment, and investigations requested were analyzed. Predictors of diagnostic delay were evaluated by multivariate linear regression, adjusting for potential confounders.Results: The median diagnostic delay from first symptom onset was 10 months. Spinal-onset, slower disease progression, cognitive symptoms at onset, and lower income were associated with increased diagnostic delay. Most patients were first assessed by general practitioners. Patients who were first evaluated by a neurologist were more likely to be correctly diagnosed, decreasing time to diagnosis. Electromyography was decisive in establishing the diagnosis.Conclusions: Late referral from non-neurologists to a neurologist is a potentially modifiable factor contributing to significant diagnostic delay. Educational interventions targeted to non-neurologists physicians, in order to increase awareness of ALS and, consequently, promote early referral to a neurologist at a tertiary center, will be important in reducing diagnostic delay.